MX2019000834A - Un derivado de oxazina para usar en la prevencion de la enfermedad de alzheimer en pacientes de riesgo. - Google Patents
Un derivado de oxazina para usar en la prevencion de la enfermedad de alzheimer en pacientes de riesgo.Info
- Publication number
- MX2019000834A MX2019000834A MX2019000834A MX2019000834A MX2019000834A MX 2019000834 A MX2019000834 A MX 2019000834A MX 2019000834 A MX2019000834 A MX 2019000834A MX 2019000834 A MX2019000834 A MX 2019000834A MX 2019000834 A MX2019000834 A MX 2019000834A
- Authority
- MX
- Mexico
- Prior art keywords
- alzheimer
- disease
- prevention
- oxazine derivative
- risk patients
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a un inhibidor de BACE-1 derivado de oxazina y composiciones farmacéuticas que comprenden dicho derivado de oxazina para usar en la prevención de la enfermedad de Alzheimer en un paciente con riesgo de desarrollar los síntomas clínicos de la enfermedad de Alzheimer y, en particular, en donde el paciente con riesgo de desarrollar los síntomas clínicos de la enfermedad de Alzheimer es portador de una o dos copias del alelo ApoE4.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16180233 | 2016-07-19 | ||
EP16193779 | 2016-10-13 | ||
PCT/IB2017/054307 WO2018015868A1 (en) | 2016-07-19 | 2017-07-17 | An oxazine derivative for use in the prevention of alzheimer's disease in at risk patients |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019000834A true MX2019000834A (es) | 2019-07-04 |
Family
ID=59626646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019000834A MX2019000834A (es) | 2016-07-19 | 2017-07-17 | Un derivado de oxazina para usar en la prevencion de la enfermedad de alzheimer en pacientes de riesgo. |
Country Status (18)
Country | Link |
---|---|
US (2) | US20180036315A1 (es) |
EP (1) | EP3487504A1 (es) |
JP (1) | JP2019524743A (es) |
KR (1) | KR20190030691A (es) |
CN (1) | CN109475562A (es) |
AU (1) | AU2017298651A1 (es) |
BR (1) | BR112019000902A2 (es) |
CA (1) | CA3028629A1 (es) |
CL (1) | CL2019000122A1 (es) |
IL (1) | IL264040A (es) |
JO (1) | JOP20190003A1 (es) |
MA (1) | MA45719A (es) |
MX (1) | MX2019000834A (es) |
PH (1) | PH12018502703A1 (es) |
RU (1) | RU2019101210A (es) |
SG (1) | SG11201811022TA (es) |
TW (1) | TW201805004A (es) |
WO (1) | WO2018015868A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190081A1 (ar) | 2016-10-13 | 2019-04-11 | Novartis Ag | مشتق أوكسازين للاستخدام في علاج أو الوقاية من اعتلال وعائي دماغي نشواني |
CN113209087B (zh) * | 2020-02-05 | 2023-11-07 | 歌礼药业(浙江)有限公司 | 一种抑制冠状病毒的药物组合物及其用途 |
KR102321601B1 (ko) * | 2020-11-19 | 2021-11-05 | 주식회사 휴런 | 뇌 영상을 이용한 알츠하이머병의 생물학적 분류 장치 및 방법 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5715710B2 (ja) | 2011-01-13 | 2015-05-13 | ノバルティス アーゲー | 新規複素環誘導体および神経障害の処置におけるそれらの使用 |
IN2014DN03206A (es) * | 2011-10-13 | 2015-05-22 | Novartis Ag |
-
2017
- 2017-06-16 JO JOP/2019/0003A patent/JOP20190003A1/ar unknown
- 2017-07-17 WO PCT/IB2017/054307 patent/WO2018015868A1/en active Application Filing
- 2017-07-17 CA CA3028629A patent/CA3028629A1/en not_active Abandoned
- 2017-07-17 MA MA045719A patent/MA45719A/fr unknown
- 2017-07-17 US US15/651,845 patent/US20180036315A1/en not_active Abandoned
- 2017-07-17 RU RU2019101210A patent/RU2019101210A/ru not_active Application Discontinuation
- 2017-07-17 BR BR112019000902-7A patent/BR112019000902A2/pt not_active Application Discontinuation
- 2017-07-17 CN CN201780043581.9A patent/CN109475562A/zh active Pending
- 2017-07-17 TW TW106123742A patent/TW201805004A/zh unknown
- 2017-07-17 SG SG11201811022TA patent/SG11201811022TA/en unknown
- 2017-07-17 EP EP17752181.2A patent/EP3487504A1/en not_active Withdrawn
- 2017-07-17 JP JP2019502566A patent/JP2019524743A/ja active Pending
- 2017-07-17 MX MX2019000834A patent/MX2019000834A/es unknown
- 2017-07-17 KR KR1020197001453A patent/KR20190030691A/ko unknown
- 2017-07-17 AU AU2017298651A patent/AU2017298651A1/en not_active Abandoned
-
2018
- 2018-12-20 PH PH12018502703A patent/PH12018502703A1/en unknown
- 2018-12-31 IL IL264040A patent/IL264040A/en unknown
-
2019
- 2019-01-16 CL CL2019000122A patent/CL2019000122A1/es unknown
-
2020
- 2020-07-17 US US16/931,783 patent/US20200345746A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL264040A (en) | 2019-01-31 |
JOP20190003A1 (ar) | 2019-01-10 |
CA3028629A1 (en) | 2018-01-25 |
MA45719A (fr) | 2019-05-29 |
US20200345746A1 (en) | 2020-11-05 |
AU2017298651A1 (en) | 2018-12-20 |
SG11201811022TA (en) | 2019-02-27 |
EP3487504A1 (en) | 2019-05-29 |
CN109475562A (zh) | 2019-03-15 |
PH12018502703A1 (en) | 2019-11-11 |
JP2019524743A (ja) | 2019-09-05 |
KR20190030691A (ko) | 2019-03-22 |
CL2019000122A1 (es) | 2019-04-12 |
US20180036315A1 (en) | 2018-02-08 |
WO2018015868A1 (en) | 2018-01-25 |
RU2019101210A (ru) | 2020-08-19 |
BR112019000902A2 (pt) | 2019-04-30 |
TW201805004A (zh) | 2018-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019003363A (es) | Composiciones farmaceuticas para usarse en la terapia de la blefaritis. | |
PH12016502256A1 (en) | Medical use | |
CO6602152A2 (es) | En respuesta al requerimiento de pago de reivindicaciones adicionales a las 10 primeras,presenta nuevo capítulo reivindicatorio y paga. | |
MX2021010696A (es) | Composiciones farmaceuticas que comprenden un compuesto de dextrometorfano y quinidina para el tratamiento de agitacion en demencia. | |
MX2019003805A (es) | Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías. | |
MX2021006884A (es) | Compuestos y su uso para el tratamiento de la deficiencia de alfa1-antitripsina. | |
PH12018502703A1 (en) | An oxazine derivative for use in the prevention of alzheimer's disease in at risk patients | |
BR112017022158A2 (pt) | compostos, composições farmacêuticas e uso de um composto | |
CY1121707T1 (el) | Αναστολεας πρωτεϊνης μεταφορας εστερων χοληστερολης (cetp) και φαρμακευτικες συνθεσεις που περιλαμβανουν τον εν λογω αναστολεα για χρηση στη θεραπεια ή την προληψη καρδιαγγειακων νοσηματων | |
MA38369B1 (fr) | Peptides et compositions pour le traitement d'une lesion de l'articulation | |
MX2018001592A (es) | Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos. | |
MA39447B1 (fr) | Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
BR112018073419A2 (pt) | combinação, uso da combinação, método para o tratamento, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
MY186523A (en) | Macrocyclic rip2 kinase inhibitors | |
MX2020001256A (es) | Compuestos para la prevencion y el tratamiento de trastornos medicos y usos de los mismos. | |
MA39448B1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
BR112019002355A2 (pt) | composições e métodos para prevenção de acidente vascular cerebral em pacientes pediátricos com anemia falciforme | |
BR112018073396A2 (pt) | combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica | |
CO2019007671A2 (es) | Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer | |
MY179462A (en) | Protective effects of oil palm composition on alzheimer?s disease | |
CY1119674T1 (el) | Θεραπεια και προληψη της νοσου αλτσχαϊμερ (ad) | |
MX2018006631A (es) | Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas. | |
PH12019500464A1 (en) | An oxazine derivative for use in the treatment or prevention of cerebral amyloid angiopathy | |
EA201790020A1 (ru) | Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний | |
WO2015189830A9 (en) | Dual inhibitor compounds for use in the treatment of neurodegenerative disorders and alzheimer's disease |